1212P IMpower010: Characterisation of Patients (pts) with Stage II-IIIA PD-L1 TC≥50% NSCLC Who Were Disease-Free at 5 Years (5ydf) in a Phase III Study of Atezolizumab (atezo) Vs Best Supportive Care (BSC) after Resection and Adjuvant (adj) Chemotherapy (Chemo)